Molecular Medicine News

Creative Enzymes Launches DSPE-PEG-Maleimide for Targeted Drug Delivery

Creative Enzymes, a professional enzyme provider located in New York, always hammers at researches and trials in order to provide customers with various enzymes as many as possible. The product manager of Creative Enzymes announced the launch of DSPE-PEG(5000) Maleimide and DSPE-PEG(2000) Maleimide, which can be used to synthesize functional conjugates. DSPE-PEG-Maleimide (DSPE-PEG-MAL) is a ...

Jun. 22, 2021

By Creative Enzymes

Creative Enzymes Upgrades Multiple Diagnostic Enzyme Products for Clinical and Diagnostic Research

Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained solid reputation. Recently, Creative Enzymes has announced multiple ...

May 25, 2021

By Creative Enzymes

Thermo Fisher Scientific Recognizes Significance of FDA Approval of First CAR T Cell Immunotherapy for Multiple Myeloma with Donation to Leukemia and Lymphoma Society

Thermo Fisher Scientific Inc. has made a donation to the Leukemia & Lymphoma Society in recognition of the recent U.S. Food and Drug Administration approval of the first CAR T cell immunotherapy for multiple myeloma developed by Bristol Myers Squibb and bluebird bio. Abecma® (idecabtagene vicleucel; ide-cel) is a chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of ...

Apr. 28, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

MediPines AGM100 Voted as Finalist in Medical Design Excellence Awards, MDEA 2021

We are pleased to announce that MediPines AGM100, a non-invasive pulmonary gas exchange analyzer, was selected as a finalist in the 2021 Medical Design Excellence Awards (MDEA). The MDEAs is the premier design competition in the MedTech industry organized by MD+DI and recognizes the significant achievements in medical product design and engineering that improve the quality of healthcare delivery ...

Apr. 27, 2021

By MediPines

Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced new data from preclinical studies of its GalXC-Plus™ RNAi technology demonstrating its potential to deliver deep and sustained messenger RNA (mRNA) knockdown against prespecified gene ...

Mar. 30, 2021

By Dicerna Pharmaceuticals, Inc.

Immunai Acquires Dropprint Genomics and Strengthens Leadership Team with Experts in Immunology to Expand Target Discovery Capabilities

Immunai, a New York and Tel Aviv-based biotech company, announced its acquisition of Dropprint Genomics, a San Francisco-based single-cell genomics software company. Immunai is also expanding its executive leadership team and scientific advisory board with experts in immunology, single-cell technologies and machine learning. Both the acquisition and new hires will advance the company’s work ...

Mar. 25, 2021

By Immunai

Immunai acquires single-cell data developer Dropprint Genomics to build out its immune system atlas

Shortly after raising $60 million to fuel its artificial intelligence work, aimed at digitally charting the human body’s immune system, Immunai announced it has acquired the single-cell sequencing software startup Dropprint Genomics. Previously backed by Y Combinator, the San Francisco-based Dropprint aims to provide big data and machine learning solutions to help crunch the numbers ...

Mar. 25, 2021

By Immunai

Seven Bridges Launches the GRAFTM Population Solution

Seven Bridges, the industry-leading bioinformatics ecosystem provider, today announced the launch of the GRAFTM Population Solution, a set of workflows, services and population-specific graph references to enable large-scale human population studies through more accurate read alignment and variant discovery. Included in today’s release are an updated population-specific NGS analysis ...

Mar. 24, 2021

By Seven Bridges Genomics

Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the dosing of the first patient as part of the HPV001 clinical study. HPV001 is a randomized, placebo-controlled Phase 1/2 clinical trial designed to evaluate the safety and ...

Mar. 18, 2021

By Vaccitech Limited

Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results

Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announces that it has raised $168 million in a Series B financing. This includes $43 million in convertible loan notes previously issued by Vaccitech that ...

Mar. 17, 2021

By Vaccitech Limited

Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics

Inflammatix, a pioneering molecular diagnostics company, announced today the closing of a $102 million Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF ...

Mar. 16, 2021

By Inflammatix, Inc.

INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the appointment of Michael Cordera as Executive Vice President and General Counsel. Mr. Cordera will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive ...

Mar. 15, 2021

By INOVIO Pharmaceuticals

INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results

INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended December 31, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss ...

Mar. 1, 2021

By INOVIO Pharmaceuticals

INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18

INOVIO, (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, today announced it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial. This trial is one of two ongoing pivotal, randomized, double-blind, multi-center, ...

Mar. 1, 2021

By INOVIO Pharmaceuticals

INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO`s VGX-3100 for advanced cervical dysplasia

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies. (*Complementary when referring to the US regulatory pathway.) The ...

Feb. 24, 2021

By INOVIO Pharmaceuticals

INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the first participant was dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Ghana. The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute ...

Feb. 23, 2021

By INOVIO Pharmaceuticals

Thermo Fisher Scientific Announces Oncomine Clinical Research Grant 2021 Call for Submissions

Thermo Fisher Scientific has opened a call for submissions for its Oncomine Clinical Research Grant program to support clinical research. The program aims to assist educational and independent research projects that exhibit excellence in molecular profiling to advance clinical outcomes and support health care providers serving cancer patients. After initially launching the grant program in 2020, ...

Feb. 23, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

Immunai Raises $60M to Reprogram Immunity

Immunai, a New York and Tel Aviv based biotech company, announced today $60M in funding, increasing the company’s total funding-to-date to over $80M. Immunai integrates multi-omic single-cell analytics and machine learning to identify novel immunological insights that lead to the discovery and development of more effective and targeted immunotherapies. The Series A round was led by ...

Feb. 11, 2021

By Immunai

Kayan Health Partners with Predictiv Care, Inc. to Offer DNA-based and AI Powered Medical Consultations

Beyond Medical Technologies Inc. (“Beyond Medical” or the “Company“) (CSE: DOCT) (Frankfurt: 7FM3), is pleased to state that further to its news release dated January 14, 2021, announcing its letter of intent with Kayan Health Limited (“Kayan Health“), Kayan Health has signed a Memorandum of Understanding (“MoU”) with Predictiv Care, Inc. ...

Feb. 9, 2021

By Micron Waste Technologies

Study Finds MediPines’ Breakthrough Non-invasive Gas Exchange Method Highly Precise: Ideal for Covid Response

A recent clinical study published by medical researchers from UC San Diego School of Medicine has established that an expired breath sampling method is comparable to the long-established blood-based method (ABG) of measuring pulmonary gas exchange efficiency. Published in the American Journal of Physiology Lung Cellular and Molecular Physiology, the study, entitled “Measuring the ...

Feb. 1, 2021

By MediPines